Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet

Study Identifier
P06-131
CT.gov Identifier
NCT01097655
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Human Immunodeficiency Virus (HIV)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients with HIV infection * Patients that will be treated with Kaletra tablets independent from their participation in this study
    Exclusion Criteria:
    * Hypersensitivity against Kaletra or other ingredients * Severe liver insufficiency * No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort * Patients who received more than 1 protease inhibitor during their therapy history

    Protocol Summary

    The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra (lopinavir/ritonavir) tablets in human immunodeficiency virus (HIV)-infected patients. In some patients, the study is to show the impact on tolerability of changing therapy to Kaletra tablets from other regimens.

    Study Locations

    No locations found.